ArticleMolecular and cellular biochemistry2010
The anticancer drug perillyl alcohol is a Na/K-ATPase inhibitor.
Article in Molecular and cellular biochemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Directed evolution of a cytochrome P450 monooxygenase for improved perillyl alcohol biosynthesisRSC advances · 2026Article
- Intranasal Terpene Treatment for Glioblastoma: the Neuro-Oncological Potential of Perillyl Alcohol.Neurochemical research · 2025Review
- Article
- Perillyl Alcohol Promotes Relaxation in Human Umbilical Artery.Current medicinal chemistry · 2024Article
- Incorporation of Perillyl Alcohol into Lipid-Based Nanocarriers Enhances the Antiproliferative Activity in Malignant Glioma Cells.Biomedicines · 2023Article
- The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.Pharmaceutics · 2021Review
- NovelRSC advances · 2019Article
- Biochemical significance of limonene and its metabolites: future prospects for designing and developing highly potent anticancer drugs.Bioscience reports · 2018Review
- Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development.International journal of molecular sciences · 2018Review
- Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram.International journal of molecular sciences · 2018Article
- The Na, K-ATPase β-Subunit Isoforms Expression in Glioblastoma Multiforme: Moonlighting Roles.International journal of molecular sciences · 2017Article
- Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas.Surgical neurology international · 2016Article
- Pseudomonas putida-a versatile host for the production of natural products.Applied microbiology and biotechnology · 2015Review
- Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol.Molecular cancer · 2015Article
- Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.American journal of cancer research · 2015Review
- The identification of perillyl alcohol glycosides with improved antiproliferative activity.Journal of medicinal chemistry · 2014Article
- Chemical composition, antioxidant, anti-inflammatory and anti-proliferative activities of essential oils of plants from Burkina Faso.PloS one · 2014Article
- Antitumor activity of monoterpenes found in essential oils.TheScientificWorldJournal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The monoterpene perillyl alcohol (POH) is a drug used in the treatment of several malignant tumors, including gliomas. The present study defines a POH inhibitory effect on Na/K-ATPase activity from kidney and brain guinea pig extracts and from a human glioblastoma cell line. This inhibition showed a high degree of selectivity toward the kidney enzyme expressing, as do glioblastoma cells, the α(1) subunit. Kinetic studies with purified enzymes showed a noncompetitive POH inhibition profile to Na(+) and K(+) and an uncompetitive inhibition towards ATP. Furthermore, potassium activated p-nitrophenylphosfatase activity of these purified preparations was not inhibited by POH, suggesting that this drug, differently from the classical inhibitor ouabain, acted in the initial phase of the enzyme's catalytic cycle. We suggest that POH antitumor action could be linked to its Na/K-ATPase binding properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.